Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Oncolytics Biotech Q3 2026 Results: Net Loss of $9.71M, Loss Narrows

Oncolytics Biotech Inc. reported a net loss of $28.4 million for the nine months ended September 30, 2026, compared to $19.9 million in the prior year period, driven by increased R&D and G&A expenses. The company's cash position decreased to $2.4 million, leading management to issue a going concern warning as existing resources are insufficient to fund operations for the next twelve months.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-9.7-10.1
Net income-9.7-9.9
EPS (diluted, $ a share)$-0.08$-0.10

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ONCY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Oncolytics Biotech Inc: key numbers

Share price
$0.3399Close, Nov 16
Market cap
$46.3M
Shares outstanding
136.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Oncolytics Biotech Inc

All →
8:02 AM ET 8-K
Research Collaboration

Oncolytics Biotech Research Collaboration with Coherus Oncology, Inc.

Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate pelareorep in combination with LOQTORZI (toripalimab-tpzi) for the treatment of squamous cell anal carcinoma (SCAC). The clinical study, expected to begin in Q1 2027, will target second-line patients who have progressed on standard-of-care treatments.

Counterparty
Coherus Oncology, Inc.
9:49 AM ET 8-K
Clinical Trial Data

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced translational data from a Phase 1b/2 trial evaluating pelareorep in patients with relapsed/refractory multiple myeloma. Single-cell sequencing demonstrated that pelareorep engaged the immune system, remodeled the tumor microenvironment, and increased populations of CD8 effector memory T cells. The data, which showed greater T cell expansion in clinical responders, will be presented at the 68th ASH Annual Meeting.

9:37 AM ET 8-K
Clinical Trial Data

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced translational data from an ongoing Phase 1/2 study of pelareorep in combination with a checkpoint inhibitor for squamous cell anal cancer (SCAC). The data showed that the treatment more than doubled immune activation levels in nearly all patients and expanded HPV-16-specific T cell clones, which was associated with tumor shrinkage and objective responses.

9:46 AM ET 8-K
Clinical Trial Data

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination with atezolizumab for squamous cell anal cancer (SCAC). The study demonstrated a median duration of response of approximately 15 months, with 100% of responding patients surviving longer than one year, supporting a potential registration path in HPV-driven cancers.

9:38 AM ET 8-K
Business Update

Oncolytics Biotech Business Update

Oncolytics Biotech announced it will present a trial-in-progress abstract and e-poster for its REO 033 study at the ESMO Congress 2026. The study is a randomized Phase 2 trial evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line treatment of RAS-mutant, microsatellite-stable metastatic colorectal cancer.

9:33 AM ET 8-K
Business Update

Oncolytics Biotech Business Update

Oncolytics Biotech provided an operational update on its GOBLET Phase 1/2 study, announcing the completion of enrollment and the expected receipt of a final grant payment from the Pancreatic Cancer Action Network (PanCAN). The company expects to report final results from Cohort 4 in Q4 2026 and initial results from Cohort 5 in the first half of 2027.

Counterparty
Pancreatic Cancer Action Network

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.